BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

189 related articles for article (PubMed ID: 14566681)

  • 1. Clinical study of urine NMP 22 (nuclear matrix protein 22) as a tumor marker in urinary epithelial cancer.
    Takeuchi Y; Sawada Y; Yabuki D; Masuda E; Satou D; Kuroda K; Tajima M; Sawamura Y; Matsushima M
    Aktuelle Urol; 2003 Jul; 34(4):265-6. PubMed ID: 14566681
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Evaluation of urinary NMP22 (nuclear matrix protein 22) as a diagnostic marker for urothelial cancer--NMP22 as a urinary marker for surveillance of bladder cancer. NMP22 Study Group].
    Akaza H; Miyanaga N; Tsukamoto T; Ishikawa S; Noguchi R; Ohtani M; Kawabe K; Kubota Y; Fujita K; Obata K; Hirao Y; Kotake T; Ohmori H; Kumazawa J; Koiso K
    Gan To Kagaku Ryoho; 1997 May; 24(7):829-36. PubMed ID: 9170521
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Evaluation of urinary NMP22 (nuclear matrix protein 22) as a diagnostic marker for urothelial cancer--screening for urothelial cancer in patients with microscopic hematuria. NMP Study Group].
    Akaza H; Miyanaga N; Tsukamoto T; Ishikawa S; Noguchi R; Ohtani M; Kawabe K; Kubota Y; Fujita K; Obata K; Hirao Y; Kotake T; Ohmori H; Kumazawa J; Koiso K
    Gan To Kagaku Ryoho; 1997 May; 24(7):837-42. PubMed ID: 9170522
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Urinary tumor marker for urothelial cancer].
    Ohtani M; Iwasaki A; Shiraiwa H
    Gan To Kagaku Ryoho; 2001 Nov; 28(12):1933-7. PubMed ID: 11729491
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Clinical evaluation of urinary NMP22 (nuclear matrix protein 22) bladder chek in the detection of patients with bladder cancer].
    Kitsukawa S; Yamamoto Y; Hosoda S; Otsuru N; Matsumoto T; Matsumoto T; Aizawa T; Noda K; Ito T
    Hinyokika Kiyo; 2006 Mar; 52(3):167-72. PubMed ID: 16617867
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Clinical evaluation of urinary nuclear matrix protein 22 as a marker for bladder cancer].
    Kurokawa S; Morita T; Muraishi O; Tokue A
    Hinyokika Kiyo; 2001 Apr; 47(4):247-50. PubMed ID: 11411098
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Evaluation of nuclear matrix protein-22 as a clinical diagnostic marker for bladder cancer.
    Chang YH; Wu CH; Lee YL; Huang PH; Kao YL; Shiau MY
    Urology; 2004 Oct; 64(4):687-92. PubMed ID: 15491702
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Availability of NMP22 (nuclear matrix protein 22) for the diagnosis of urothelial cancer].
    Akagashi K; Tanda H; Kato S; Ohnishi S; Nakajima H; Nanbu A; Nitta T; Koroku M
    Hinyokika Kiyo; 2001 May; 47(5):307-10. PubMed ID: 11433749
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Enhanced urinary gelatinase activities (matrix metalloproteinases 2 and 9) are associated with early-stage bladder carcinoma: a comparison with clinically used tumor markers.
    Sier CF; Casetta G; Verheijen JH; Tizzani A; Agape V; Kos J; Blasi F; Hanemaaijer R
    Clin Cancer Res; 2000 Jun; 6(6):2333-40. PubMed ID: 10873084
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Screening methods in the detection of bladder cancer: comparison of nuclear matrix protein-22, bladder tumor antigen and cytological examinations].
    Fukui Y; Samma S; Fujimoto K; Akiyama T; Yamaguchi A; Hirayama A
    Hinyokika Kiyo; 2001 May; 47(5):311-4. PubMed ID: 11433750
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Usefulness of urinary nuclear matrix protein 22 (NMP22) as a marker for transitional cell carcinoma of the bladder.
    Menendez V; Filella X; Alcover JA; Molina R; Mallafre JM; Ballesta AM; Talbot-Wright R
    Anticancer Res; 2000; 20(2B):1169-72. PubMed ID: 10810416
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [The clinical efficacy of Bladder Chek NMP22 in urothelial cancer].
    Yokoyama T; Sekigawa R; Hayashi T; Horita S; Kanamuro T; Nonami Y; Sawada T; Nishikawa T; Kobayashi M; Yamaguchi Y; Ishida H; Goya N; Nakazawa H; Toma H
    Rinsho Byori; 2004 Mar; 52(3):199-203. PubMed ID: 15137316
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Risk stratification for bladder tumor recurrence, stage and grade by urinary nuclear matrix protein 22 and cytology.
    Shariat SF; Casella R; Wians FH; Ashfaq R; Balko J; Sulser T; Gasser TC; Sagalowsky AI
    Eur Urol; 2004 Mar; 45(3):304-13; author reply 313. PubMed ID: 15036675
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparisons of voided urine cytology, nuclear matrix protein-22 and bladder tumor associated antigen tests for bladder cancer of geriatric male patients in Taiwan, China.
    Tsui KH; Chen SM; Wang TM; Juang HH; Chen CL; Sun GH; Chang PL
    Asian J Androl; 2007 Sep; 9(5):711-5. PubMed ID: 17712491
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Could nuclear matrix protein 22 (NMP22) play a role with urine cytology in screening for bladder cancer?--experience at Kuwait University.
    Kapila K; Kehinde EO; Anim JT; Mojiminiyi OA; Vinsu A; George SS; Al-Maghrebi M; Al-Mulla F
    Cytopathology; 2008 Dec; 19(6):369-74. PubMed ID: 18631356
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [NMP-22 test. Is it useful in the follow-up of patients with superficial bladder tumor?].
    Pérez García FJ; Eyo A; Escaf Barmadah S; Fernández Gómez JM
    Arch Esp Urol; 2002 Dec; 55(10):1201-8. PubMed ID: 12611217
    [TBL] [Abstract][Full Text] [Related]  

  • 17. NMP-22, urinary cytology, and cystoscopy: a 1 year comparison study.
    Schlake A; Crispen PL; Cap AP; Atkinson T; Davenport D; Preston DM
    Can J Urol; 2012 Aug; 19(4):6345-50. PubMed ID: 22892257
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prognostic value of cytology, nuclear matrix protein 22 (NMP22) test, and urinary bladder cancer II (UBC II) test in early recurrent transitional cell carcinoma of the bladder.
    Kibar Y; Goktas S; Kilic S; Yaman H; Onguru O; Peker AF
    Ann Clin Lab Sci; 2006; 36(1):31-8. PubMed ID: 16501234
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparison of NMP22 BladderChek test and urine cytology for the detection of recurrent bladder cancer.
    Kumar A; Kumar R; Gupta NP
    Jpn J Clin Oncol; 2006 Mar; 36(3):172-5. PubMed ID: 16520358
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Urinary levels of tumor-associated trypsin inhibitor (TATI) in the detection of transitional cell carcinoma of the urinary bladder.
    Shariat SF; Herman MP; Casella R; Lotan Y; Karam JA; Stenman UH
    Eur Urol; 2005 Sep; 48(3):424-31. PubMed ID: 15963628
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.